Related Experiment Videos
Abstract:
Numerous investigators have reported on a variety of chemotherapeutic agents tested in children suffering from recurrent medulloblastoma, brain stem glioma, and ependymoma, in efforts to improve survival and reduce morbidity. Evaluation of such studies is difficult, because there were rarely more than three or four cases of each tumor type. In medulloblastoma, 5-year survival averages 32%; recurrence follows initial therapy by months to years. The recurrence may be intracranial, spinal, or metastatic, making comparison among cases very difficult. Intrathecal methotrexate (MTX) has been successfully used to treat medulloblastoma, with responses reported in about three-fourths of the cases. Intraventricular MTX is lethal when ventricular obstruction is present. MTX has been less useful in therapy of brain stem glioma and ependymoma. BCNU and CCNU have produced responses in patients with ependymoma, medulloblastoma, and brain stem glioma. Vincristine, alone or in combination, has been useful primarily in medulloblastomas. Less experience is available with several newer methods of chemotherapy, but promising results have been reported with procarbazine, 4'-demethyl-epipodophyllotoxin-beta-D-thenylidine-glucosede (PTG, VM 26), and high dose intravenous methotrexate with citrovorum rescue. It is likely that only a nationwide cooperative effort will achieve significant improvement in the chemotherapy of malignant brain tumors in children.
Insights
Chemotherapy for recurrent pediatric brain tumors like medulloblastoma shows promise with agents like methotrexate (MTX), BCNU, CCNU, and vincristine. Further research and cooperative efforts are essential for improved outcomes.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Chemotherapy Research
Background:
- Recurrent medulloblastoma, brain stem glioma, and ependymoma in children have limited treatment options and poor prognoses.
- Evaluating chemotherapy efficacy is challenging due to small case numbers and varied recurrence patterns (intracranial, spinal, metastatic).
Purpose of the Study:
- To review and evaluate various chemotherapeutic agents used in treating recurrent pediatric malignant brain tumors.
- To identify promising agents and strategies for improving survival and reducing morbidity in these challenging cases.
Main Methods:
- Review of existing literature on chemotherapeutic agents tested in children with recurrent medulloblastoma, brain stem glioma, and ependymoma.
- Analysis of reported response rates, survival data, and toxicities associated with different agents.
Main Results:
- Intrathecal methotrexate (MTX) showed significant response rates in medulloblastoma but is contraindicated with ventricular obstruction.
- Agents like BCNU, CCNU, and vincristine demonstrated activity across multiple tumor types.
- Emerging agents such as procarbazine and VM 26, along with high-dose MTX with citrovorum rescue, show promising preliminary results.
Conclusions:
- Current chemotherapy options for recurrent pediatric brain tumors offer variable efficacy, with some agents showing promise.
- Significant improvements in treatment outcomes are likely dependent on large-scale, nationwide cooperative clinical trials.